NCT06734234 - A Study to Evaluate the Safety, Tolerability, and Effects on Blood and Urine Markers of Single Ascending Dose of GSK4771261 in Healthy Participants and Participants With Autosomal Dominant Polycystic Kidney Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 11, 2024

Primary Completion Date

September 4, 2026

Study Completion Date

September 4, 2026

Conditions

Kidney Disease

Interventions

DRUG

GSK4771261

GSK4771261 will be administered.

DRUG

Placebo matching GSK4771261

Placebo matching GSK4771261 will be administered.

Trial Locations (14)

1200

RECRUITING

GSK Investigational Site, Brussels

3000

RECRUITING

GSK Investigational Site, Leuven

28040

RECRUITING

GSK Investigational Site, Madrid

28041

RECRUITING

GSK Investigational Site, Madrid

29200

RECRUITING

GSK Investigational Site, Brest

50937

RECRUITING

GSK Investigational Site, Cologne

N6A 5A5

RECRUITING

GSK Investigational Site, London

H4J 1C5

RECRUITING

GSK Investigational Site, Montreal

08003

RECRUITING

GSK Investigational Site, Barcelona

08035

RECRUITING

GSK Investigational Site, Barcelona

CB2 0GG

RECRUITING

GSK Investigational Site, Cambridge

EX2 5DW

RECRUITING

GSK Investigational Site, Exeter

NW3 2QG

RECRUITING

GSK Investigational Site, London

NE1 4LP

RECRUITING

GSK Investigational Site, Newcastle upon Tyne